UK Gastroesophageal Reflux Disease Therapeutics Market Size & Outlook

The gastroesophageal reflux disease therapeutics market in UK is expected to reach a projected revenue of US$ 382.8 million by 2030. A compound annual growth rate of 3% is expected of UK gastroesophageal reflux disease therapeutics market from 2024 to 2030.
Revenue, 2023 (US$M)
$311.4
Forecast, 2030 (US$M)
$382.8
CAGR, 2024 - 2030
3%
Report Coverage
UK

UK gastroesophageal reflux disease therapeutics market, 2018-2030 (US$M)

UK

Related Markets

UK gastroesophageal reflux disease therapeutics market highlights

  • The UK gastroesophageal reflux disease therapeutics market generated a revenue of USD 311.4 million in 2023 and is expected to reach USD 382.8 million by 2030.
  • The UK market is expected to grow at a CAGR of 3% from 2024 to 2030.
  • In terms of segment, antacids was the largest revenue generating drug type in 2023.
  • H2 Receptor Blockers is the most lucrative drug type segment registering the fastest growth during the forecast period.


Gastroesophageal reflux disease therapeutics market data book summary

Market revenue in 2023USD 311.4 million
Market revenue in 2030USD 382.8 million
Growth rate3% (CAGR from 2023 to 2030)
Largest segmentAntacids
Fastest growing segmentH2 Receptor Blockers
Historical data2018 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationAntacids, H2 Receptor Blockers, Proton Pump Inhibitors (PPIs), Pro-kinetic agents
Key market players worldwideAstraZeneca PLC, Eisai Co Ltd, GSK PLC, Takeda Pharmaceutical Co Ltd, Ironwood Pharmaceuticals Inc Class A, Johnson & Johnson, Phathom Pharmaceuticals Inc Ordinary shares


Other key industry trends

  • In terms of revenue, UK accounted for 5.9% of the global gastroesophageal reflux disease therapeutics market in 2023.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Europe, UK gastroesophageal reflux disease therapeutics market is projected to lead the regional market in terms of revenue in 2030.
  • UK is the fastest growing regional market in Europe and is projected to reach USD 382.8 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Gastroesophageal Reflux Disease Therapeutics Market Companies

Name Profile # Employees HQ Website

UK gastroesophageal reflux disease therapeutics market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to gastroesophageal reflux disease therapeutics market will help companies and investors design strategic landscapes.


Antacids was the largest segment with a revenue share of 56.68% in 2023. Horizon Databook has segmented the UK gastroesophageal reflux disease therapeutics market based on antacids, h2 receptor blockers, proton pump inhibitors (ppis), pro-kinetic agents covering the revenue growth of each sub-segment from 2018 to 2030.


According to an article published by National Center for Biotechnology Information in 2014, in the UK, 5 out of 1,000 people suffer from GERD. Organizations such as Living with Reflux, Campaign Against Reflux Disease (CARD).

Core (Digestive Disorders Foundation) are responsible for educating people and funding research pertaining to GERD. These organizations organize weekend events, coffee mornings, and walking & cycling events to create awareness.

For instance, Living with Reflux hosts marathon once a year to raise funds for babies and children with GERD.

Reasons to subscribe to UK gastroesophageal reflux disease therapeutics market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of UK gastroesophageal reflux disease therapeutics market databook

  • Our clientele includes a mix of gastroesophageal reflux disease therapeutics market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the UK gastroesophageal reflux disease therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into UK gastroesophageal reflux disease therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

UK gastroesophageal reflux disease therapeutics market outlook size, by drug type, 2018-2030 (US$M)

UK Gastroesophageal Reflux Disease Therapeutics Market Outlook Share, 2023 & 2030 (US$M)

UK gastroesophageal reflux disease therapeutics market outlook size, by drug type, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more